湖北亨迪药业股份有限公司（以下简称"公司"或"本公司"） 于 2025 年 7 月 31 日召开第二届董事会第十四次会议，审议通过了《关 于召开 2025 年第一次临时股东大会的议案》，公司决定于 2025 年 8 月 18 日在本公司会议室召开 2025 年第一次临时股东大会（以下简称 "本次股东大会"）。本次股东大会将采用现场投票和网络投票相结 合的方式，根据有关规定，现将股东大会的相关事项通知如下： 一、召开股东大会基本情况 1、股东大会届次：2025 年第一次临时股东大会 2、股东大会的召集人：公司董事会 证券代码：301211 证券简称：亨迪药业 公告编号：2025-034 湖北亨迪药业股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时 间为 2025 年 8 月 18 日交易日上午 9:15～9:25，9:30～11:30,下午 13:00～15:00； 通过深圳证券交易所互联网投票系统投票的开始时间（2025 年 8 月 18 日 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-029 湖北亨迪药业股份有限公司 第二届监事会第十三次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届监事会第十三次会 议于 2025 年 7 月 25 日以电话及邮件方式送达至全体监事，本次会议于 2025 年 7 月 31 日以现场方式召开。本次会议应参会监事 3 人，实际参会监事 3 人。会 议由监事会主席陈吉人先生召集并主持。本次会议的召集、召开和表决程序符合 《中华人民共和国公司法》和《公司章程》的有关规定，会议合法、有效。 二、监事会会议审议情况 会议审议并通过了如下议案： 1、《2025 年半年度报告》及摘要 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）刊载的《2025 年半年度报告》和在《中国证券报》、《上海证券报》、《证券时报》刊载的《2025 年半年度报告摘要》。 表决结果：3 票同意、0 票反对、0 票弃权。 该项议案获审议通过。 2、《关于对 2025 年半年 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025-028 湖北亨迪药业股份有限公司 第二届董事会第十四次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 本议案已经公司董事会审计委员会审议通过。 表决结果：赞成 8 票，反对 0 票，弃权 0 票。该项议案获审议通过。 2、《2025 年半年度募集资金存放与实际使用情况的专项报告》 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第十四次会 议于 2025 年 7 月 25 日以电话及邮件方式送达至全体董事，本次会议于 2025 年 7 月 31 日以现场和通讯方式召开。本次会议应参会董事 8 人，实际参会董事 8 人，公司监事、高级管理人员列席会议，本次会议由公司董事长程志刚主持。本 次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规和《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 1、《2025 年半年度报告》及摘要 经审议，董事会认为：公司《2025 年半年度报告》及《2025 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2025- 033 湖北亨迪药业股份有限公司关于 2025 年半年度利润分配预案的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于 2025 年 7 月 31 日召开 第二届董事会第十四次会议及第二届监事会第十三次会议，会议审议通过了 《关于 2025 年度半年度利润分配预案的议案》。该预案尚需提交公司 2025 年 第一次临时股东大会审议。现将相关事宜公告如下： 一、2025 年半年度利润分配预案的基本情况 本次利润分配预案分配基准为 2025 年半年度。经大信会计师事务所（特殊 普通合伙）审计，并出具标准无保留意见审计报告确认，公司 2025 年半年度合 并报表归属于母公司所有者的净利润 18,574,082.58 元，未分配利润 154,101,809.50 元；母公司净利润 16,442,287.86 元，未分配利润 166,996,976.63 元。根据合并报表和母公司报表中未分配利润孰低原则，公司 2025 年半年度可 供分配利润为 154, ...

格隆汇7月31日丨亨迪药业(301211.SZ)公布2025年半年度报告，上半年公司实现营业收入2.35亿元，同 比下降2.93%；归属于上市公司股东的净利润1854.71万元，同比下降72.92%；归属于上市公司股东的扣 除非经常性损益的净利润441.62万元，同比下降93.21%；基本每股收益0.06元；拟以资本公积金向全体 股东每10股转增4.5股。 ...

[Important Notice, Table of Contents and Definitions](index=2&type=section&id=Section%201.%20Important%20Notice%2C%20Table%20of%20Contents%20and%20Definitions) This section provides important disclaimers, a table of contents, and definitions of key terms used throughout the report [Important Notice](index=2&type=section&id=Important%20Notice) The company's board of directors, supervisory board, and senior management ensure the truthfulness, accuracy, and completeness of this semi-annual report, assuming legal responsibility, and the report details risks, countermeasures, and the 2025 semi-annual profit distribution plan - The company's 2025 semi-annual profit distribution plan is: based on 288,000,000 shares, no cash dividends will be distributed, no bonus shares will be issued, and capital reserves will be converted into 4.5 shares for every 10 shares to all shareholders[3](index=3&type=chunk) - The company's responsible person, chief financial officer, and head of accounting department all declare to guarantee the truthfulness, accuracy, and completeness of the financial report in this semi-annual report[3](index=3&type=chunk) [Definitions of Professional Terms](index=5&type=section&id=Definitions) This section defines key business, technical, and regulatory terms used in the report, including Active Pharmaceutical Ingredients (API), Non-Steroidal Anti-Inflammatory Drugs (NSAID), various drug registration certifications (e.g., CEP, DMF, cGMP), and Contract Development and Manufacturing Organization (CDMO) services, providing a foundation for understanding the company's business and industry background - The report explains several core pharmaceutical industry terms, such as Active Pharmaceutical Ingredients (API), Non-Steroidal Anti-Inflammatory Drugs (NSAID), current Good Manufacturing Practices (cGMP), and Contract Development and Manufacturing Organization (CDMO) services, which helps investors understand the company's business[12](index=12&type=chunk)[13](index=13&type=chunk) [Company Profile and Key Financial Indicators](index=8&type=section&id=Section%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section presents the company's fundamental information and key financial performance indicators for the reporting period [Company Basic Information](index=8&type=section&id=I.%20Company%20Profile) This section provides the company's basic registration information, including its stock abbreviation 'Hengdi Pharmaceutical', stock code '301211', full Chinese and English names, and legal representative, among other core identity details | Item | Content | | :--- | :--- | | Stock Abbreviation | Hengdi Pharmaceutical | | Stock Code | 301211 | | Listing Exchange | Shenzhen Stock Exchange | | Legal Representative | Cheng Zhigang | [Key Accounting Data and Financial Indicators](index=9&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company experienced a significant performance decline, with operating revenue slightly decreasing by 2.93% year-on-year, while net profit attributable to shareholders plummeted by 72.92%, and non-recurring adjusted net profit sharply fell by 93.21%, with net cash flow from operating activities also decreasing by 73.71%, indicating considerable pressure on the company's profitability and cash flow | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue(RMB) | 234,768,347.93 | 241,866,955.11 | -2.93% | | Net Profit Attributable to Parent(RMB) | 18,547,082.58 | 68,496,011.31 | -72.92% | | Non-recurring Adjusted Net Profit Attributable to Parent(RMB) | 4,416,152.74 | 65,041,920.42 | -93.21% | | Net Cash Flow from Operating Activities(RMB) | 8,401,294.23 | 31,957,787.67 | -73.71% | | Basic EPS(RMB/share) | 0.06 | 0.24 | -75.00% | | Weighted Average ROE | 0.80% | 2.95% | -2.15% | | Total Assets(RMB) | 2,392,174,132.73 | 2,488,655,694.01 | -3.88% (vs. Prior Year-End) | | Net Assets Attributable to Parent(RMB) | 2,256,889,033.97 | 2,309,688,533.16 | -2.29% (vs. Prior Year-End) | [Non-Recurring Gains and Losses Items and Amounts](index=9&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to RMB 14,130,900, significantly impacting net profit, primarily comprising RMB 14,854,300 in fair value changes from financial assets held and RMB 1,671,300 in government grants | Item | Amount(RMB) | | :--- | :--- | | Fair Value Change Gains/Losses from Financial Assets and Liabilities Held by Non-Financial Enterprises | 14,854,328.10 | | Government Grants Included in Current Period P&L | 1,671,322.76 | | **Total Non-Recurring Gains and Losses** | **14,130,929.84** | [Management Discussion and Analysis (MD&A)](index=11&type=section&id=Section%203.%20Management%20Discussion%20and%20Analysis%20(MD%26A)) This section provides a comprehensive analysis of the company's operations, financial condition, and future outlook, as discussed by management [Overview of Main Businesses](index=11&type=section&id=I.%20Main%20Businesses%20During%20the%20Reporting%20Period) The company primarily engages in the research, development, production, and sales of Active Pharmaceutical Ingredients (API) and preparations, also offering CDMO services, with core products including ibuprofen and other non-steroidal anti-inflammatory APIs, while also expanding into cardiovascular and anti-tumor fields; during the reporting period, the company achieved RMB 235 million in revenue, a 2.93% year-on-year decrease, and RMB 18.55 million in net profit, a significant 72.92% year-on-year decrease, with R&D investment of RMB 15.88 million, down 17.72% year-on-year, yet several new drug projects made progress - The company's main business involves the R&D, production, and sales of Active Pharmaceutical Ingredients (API) and preparations, as well as CDMO services, forming a product system centered on non-steroidal anti-inflammatory APIs, supplemented by specialty APIs for cardiovascular and anti-tumor applications[36](index=36&type=chunk) | Financial Indicator | Amount(RMB) | YoY Change | | :--- | :--- | :--- | | Operating Revenue | 234,768,347.93 | -2.93% | | Net Profit Attributable to Parent | 18,547,082.58 | -72.92% | | R&D Investment | 15,876,209.56 | -17.72% | - During the reporting period, products such as Ibuprofen Sustained-Release Capsules and Torasemide Injection obtained drug registration certificates, and multiple R&D projects progressed smoothly[42](index=42&type=chunk) [Analysis of Core Competencies](index=15&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core competencies are evident in four key areas: R&D, through continuous process innovation to reduce ibuprofen costs and expand specialty API product lines; Production, possessing modern, automated manufacturing capabilities and a stringent quality management system; Registration, with products certified by multiple countries' GMP standards and becoming qualified suppliers to international giants like Sanofi and GlaxoSmithKline; and the integrated 'API + Preparation' model, ensuring supply chain stability, cost advantages, and enhanced risk resilience - The company continuously innovates processes for ibuprofen API to reduce production costs, develops derivative products like dexibuprofen, and expands into specialty APIs for anti-tumor and cardiovascular applications[44](index=44&type=chunk)[45](index=45&type=chunk) - The company's main API products have passed GMP certifications and drug registrations in multiple countries and regions, including China, the United States, and the European Union, successfully entering the supply chains of global pharmaceutical giants such as Sanofi, GlaxoSmithKline, and Abbott[47](index=47&type=chunk) - The integrated "API + Preparation" layout is one of the company's core advantages, ensuring raw material supply, reducing preparation costs, and securing market position through cost and quality control in the context of centralized procurement[48](index=48&type=chunk)[49](index=49&type=chunk) [Analysis of Main Business](index=17&type=section&id=III.%20Analysis%20of%20Main%20Business) During the reporting period, the company's main business costs increased by 18.45%, primarily due to a decline in API product gross margin, leading the company to adopt a volume-for-value strategy; financial expenses significantly decreased by 85.51% mainly due to reduced interest income; by product segment, non-steroidal anti-inflammatory drugs remained the largest revenue source but saw both revenue and gross margin decline, while anti-tumor products' revenue grew by 42.67% but their gross margin turned negative at -11.32%, indicating cost control challenges | Financial Item | Current Period(RMB) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | | Operating Cost | 183,347,719.02 | 18.45% | Gross margin of API products decreased, and the company increased sales volume to maintain sales revenue | | Financial Expenses | -6,011,409.88 | -85.51% | Interest income decreased in this period | | Income Tax Expense | 1,974,604.33 | -84.06% | Total profit decreased in this period | | Product Category | Operating Revenue(RMB) | Revenue YoY Change | Gross Margin | Gross Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | | Non-Steroidal Anti-Inflammatory | 159,778,817.35 | -9.35% | 15.27% | -12.58% | | Cardiovascular | 37,760,622.99 | 14.57% | 71.83% | -5.20% | | Anti-Tumor | 16,419,201.42 | 42.67% | -11.32% | -35.59% | [Analysis of Assets and Liabilities](index=18&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) As of the end of the reporting period, the company's total assets were RMB 2.392 billion, a 3.88% decrease from the beginning of the year, with no significant changes in asset composition; financial assets measured at fair value had an ending balance of RMB 1.039 billion, primarily trading financial assets (wealth management products), generating RMB 10.57 million in fair value change gains for the period; additionally, RMB 8.9 million in monetary funds were restricted as collateral - The company's financial assets measured at fair value are primarily trading financial assets (wealth management products), with an ending balance of approximately **RMB 1.03 billion**, generating **RMB 10.57 million** in fair value change gains for the current period[57](index=57&type=chunk)[58](index=58&type=chunk) - As of the end of the reporting period, **RMB 8.9 million** of the company's monetary funds were restricted as collateral[59](index=59&type=chunk) [Analysis of Investment Status](index=19&type=section&id=VI.%20Analysis%20of%20Investment%20Status) During the reporting period, the company's investment amounted to RMB 70 million, a significant 87.32% year-on-year decrease, with a cumulative utilization rate of 40.96% for raised funds; the company adjusted some fundraising projects, terminating the 'Annual Production of 5,000 Tons of Ibuprofen API Project' due to market oversupply and low prices, and extending the construction period for several other projects, including the 'High-End Pharmaceutical Preparation Internationalization Project' - Given the saturated supply and demand and low prices in the international ibuprofen API market, the company decided to terminate the "Annual Production of 5,000 Tons of Ibuprofen API Project" and reallocate part of the corresponding raised funds to other R&D and technical renovation projects[68](index=68&type=chunk) - Due to longer approval times and changes in market conditions, the company extended the estimated ready-for-use date for the "High-End Pharmaceutical Preparation Internationalization Project" to December 2026, and also extended two other API projects[67](index=67&type=chunk) [Risks and Countermeasures](index=25&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company identified five major operational risks: production safety (involving hazardous chemicals and high-temperature environments), product quality (high drug safety requirements), exchange rate fluctuations (overseas sales affected by RMB exchange rates), international trade environment (e.g., changes in China-India economic and trade relations), and pharmaceutical industry policy (e.g., centralized drug procurement); the company stated it will closely monitor and actively respond - The company faces multiple risks including production safety, product quality, exchange rate fluctuations, international trade environment, and industry policies[77](index=77&type=chunk)[78](index=78&type=chunk)[79](index=79&type=chunk)[81](index=81&type=chunk)[82](index=82&type=chunk) - Regarding international trade risks, one of the company's main raw material suppliers for isobutylbenzene is from India, and some ibuprofen products are also sold to India; changes in China-India economic and trade relations could adversely affect the company's operations[81](index=81&type=chunk) [Corporate Governance, Environment and Society (ESG)](index=26&type=section&id=Section%204.%20Corporate%20Governance%2C%20Environment%20and%20Society%20(ESG)) This section details the company's corporate governance practices, environmental initiatives, and social responsibility efforts [Profit Distribution and Capital Reserve Conversion](index=27&type=section&id=II.%20Profit%20Distribution%20and%20Capital%20Reserve%20to%20Share%20Capital%20Conversion%20in%20This%20Reporting%20Period) The company's 2025 semi-annual profit distribution plan proposes no cash dividends or bonus shares, but a capital reserve transfer of 4.5 shares for every 10 shares to all shareholders, based on a total share capital of 288,000,000 shares | Distribution/Conversion Item | Quantity | | :--- | :--- | | Bonus Shares per 10 Shares(Shares) | 0 | | Dividend per 10 Shares(RMB)(Tax Included) | 0 | | Capital Reserve Conversion per 10 Shares(Shares) | 4.5 | | Share Capital Base for Distribution Plan(Shares) | 288,000,000 | [Environmental Information Disclosure](index=28&type=section&id=IV.%20Environmental%20Information%20Disclosure) The company and its main subsidiaries have been included in the list of enterprises required to disclose environmental information by law, indicating their production and operation activities are under key supervision by environmental protection authorities, and the company must publicly disclose its environmental information as required - Hubei Hengdi Pharmaceutical Co., Ltd. has been included in the list of enterprises required to disclose environmental information by law[89](index=89&type=chunk) [Social Responsibility](index=28&type=section&id=V.%20Social%20Responsibility) The company has implemented various social responsibility measures, including protecting investor rights, caring for employees, safeguarding customer interests, and emphasizing environmental protection; the company promotes a 'low-carbon, energy-saving, green, and healthy' philosophy, achieving clean production through technological transformation and full-process control, and entrusting qualified third parties to handle its 'three wastes', with no environmental violations or irregularities reported during the period - The company emphasizes environmental protection, entrusting qualified third parties to handle its "three wastes" and strictly adhering to emission standards, with no environmental pollution incidents occurring during the reporting period[92](index=92&type=chunk) [Significant Matters](index=30&type=section&id=Section%205.%20Significant%20Matters) This section highlights significant events and commitments during the reporting period, including their fulfillment status [Fulfillment of Commitments](index=30&type=section&id=I.%20Fulfillment%20of%20Commitments%20by%20Controlling%20Shareholders%2C%20Shareholders%2C%20Related%20Parties%2C%20Acquirers%20and%20the%20Company) During the reporting period, all commitments made by the company's related parties during its initial public offering, including share lock-up and share price stabilization, were fulfilled, with no overdue unfulfilled commitments - The company's controlling shareholder, actual controller, directors, supervisors, and senior management, among other related parties, have fulfilled their share lock-up commitments and IPO share price stabilization commitments made during the initial public offering[95](index=95&type=chunk)[96](index=96&type=chunk) [Other Significant Matters](index=38&type=section&id=Other%20Significant%20Matters) During the reporting period, the company had no significant matters requiring special disclosure, such as non-operating fund occupation by controlling shareholders, illegal external guarantees, major litigation or arbitration, significant related-party transactions, or major contracts - During the reporting period, the company had no instances of controlling shareholder fund occupation, illegal guarantees, major litigation, or significant related-party transactions[104](index=104&type=chunk)[105](index=105&type=chunk)[107](index=107&type=chunk)[108](index=108&type=chunk)[121](index=121&type=chunk) [Share Changes and Shareholder Information](index=42&type=section&id=Section%206.%20Share%20Changes%20and%20Shareholder%20Information) This section outlines changes in the company's share capital and provides details on its shareholder structure [Share Change Status](index=42&type=section&id=I.%20Share%20Change%20Status) During the reporting period, the company's total share capital of 288,000,000 shares remained unchanged, with the main change being the lifting of restrictions on 216,000,000 pre-IPO restricted shares, representing 75% of the total share capital, converting them into unrestricted shares - During the reporting period, **216,000,000** restricted shares of the company were released from lock-up, accounting for **75.00%** of the company's total share capital, increasing the proportion of unrestricted shares from **25%** to **100%**[126](index=126&type=chunk)[127](index=127&type=chunk) [Number of Shareholders and Shareholding Status](index=44&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Status) As of the end of the reporting period, the company had a total of 17,134 common shareholders, with the top three being Shanghai Yongdasheng Business Consulting Co., Ltd. (38.25% stake), Liu Tianchao (12.00% stake), and Jingmen Ningkang Enterprise Management Center (Limited Partnership) (5.63% stake) - As of the end of the reporting period, the company had a total of **17,134** shareholders[130](index=130&type=chunk) | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | Shanghai Yongdasheng Business Consulting Co., Ltd. | 38.25% | 110,160,000 | | Liu Tianchao | 12.00% | 34,560,000 | | Jingmen Ningkang Enterprise Management Center (Limited Partnership) | 5.63% | 16,200,000 | [Financial Report](index=49&type=section&id=Section%208.%20Financial%20Report) This section contains the audited financial statements, key accounting policies, and detailed notes to the financial statements [Audit Report](index=49&type=section&id=I.%20Audit%20Report) This semi-annual financial report has been audited by Daxin Certified Public Accountants (Special General Partnership), which issued a standard unqualified audit opinion (Daxin Audit [2025] No. 2-01167) - The company's 2025 semi-annual financial report was audited by Daxin Certified Public Accountants, which issued a standard unqualified opinion[138](index=138&type=chunk) [Financial Statements](index=49&type=section&id=II.%20Financial%20Statements) This section provides the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity for the first half of 2025, serving as core bases for analyzing the company's financial position, operating results, and cash flows - The consolidated and parent company balance sheets as of June 30, 2025, and the income statements, cash flow statements, and statements of changes in owners' equity for the first half of 2025 are provided[138](index=138&type=chunk)[142](index=142&type=chunk)[145](index=145&type=chunk)[150](index=150&type=chunk)[155](index=155&type=chunk) [Significant Accounting Policies and Estimates](index=67&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section elaborates on the company's fundamental accounting principles, accounting period, and functional currency, and highlights significant accounting policies such as revenue recognition, financial instruments, long-term equity investments, and fixed assets; during the reporting period, the company made a significant change in accounting estimates, adjusting the capitalization point for R&D expenditures to more accurately reflect the value of R&D investments - On April 23, 2025, the company changed its accounting estimate for the capitalization point of R&D expenditures; after the change, expenditures for drugs requiring clinical trials are capitalized after entering Phase III clinical trials, and for other drugs, expenditures are capitalized after obtaining human bioequivalence clinical filing; this change resulted in an increase of **RMB 623,600.00** in development expenditures and a corresponding decrease in R&D expenses[240](index=240&type=chunk)[241](index=241&type=chunk) [Notes to Consolidated Financial Statements](index=84&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statements) This section provides detailed notes on key items in the consolidated financial statements, including: ending monetary funds of RMB 540 million, of which RMB 8.9 million is restricted; trading financial assets (wealth management products) of RMB 1.03 billion; accounts receivable ending balance of RMB 76.03 million, with a bad debt provision of RMB 7.81 million; inventory of RMB 116 million, with an impairment provision of RMB 2.03 million; and major construction in progress projects primarily being the High-End Pharmaceutical Preparation Internationalization Project and the Ibuprofen Technical Renovation Project - Ending trading financial assets amounted to **RMB 1.03 billion**, primarily consisting of bank wealth management products[248](index=248&type=chunk) - The top five accounts receivable balances at period-end totaled **RMB 18.48 million**, accounting for **24.30%** of the total[261](index=261&type=chunk) - Significant construction in progress projects include the "High-End Pharmaceutical Preparation Internationalization Project" with a budget of **RMB 332 million** and the "Ibuprofen API Wastewater Hydrolysis Acidification Project" with a budget of **RMB 86 million**[296](index=296&type=chunk) [Supplementary Information](index=117&type=section&id=XVI.%20Supplementary%20Information) This section provides a detailed statement of non-recurring gains and losses and calculations for return on net assets and earnings per share; during the reporting period, non-recurring gains and losses totaled RMB 14.13 million, primarily from fair value changes of financial assets; after deducting non-recurring gains and losses, net profit attributable to common shareholders was RMB 4.42 million, weighted average return on net assets decreased to 0.19%, and basic earnings per share was RMB 0.020 | Profit for the Period | Weighted Average ROE | Basic EPS(RMB/share) | | :--- | :--- | :--- | | Net Profit Attributable to Common Shareholders of the Company | 0.80% | 0.06 | | Net Profit Attributable to Common Shareholders of the Company After Deducting Non-Recurring Gains and Losses | 0.19% | 0.020 |

亨迪药业（301211）公告，2025年上半年营业收入2.35亿元，同比下降2.93%；净利润1854.71万元，同 比下降72.92%。公司拟以资本公积金向全体股东每10股转增4.5股。 ...

审计报告 大信审字[2025]第 2-01167 号 湖北亨迪药业股份有限公司 大信会计师事务所(特殊普通合伙) WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 报告编码:京25LYQNMBI 1 WUYIGE Certified Public Accountants Room 2206 22/F Xuevuan International Tower No 1 Zhichun Road Haidian Dist Beijing.China.100083 审 计 报 告 大信审字[2025]第 2-01167 号 湖北亨迪药业股份有限公司全体股东: 一、审计意见 我们审计了湖北亨迪药业股份有限公司(以下简称"贵公司")的财务报表,包括 2025 年 6 月 30 日的合并及母公司资产负债表,2025年 1-6 月的合并及母公司利润表、合并及母公 司现金流量表、合并及母公司股东权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规 ...

金融界消息 截至2025年7月29日收盘，亨迪药业（301211）报收于19.8元，下跌1.64%，换手率3.74%， 成交量10.76万手，成交金额2.13亿元。 资金流向方面，今日主力资金净流出1857.26万元，占比成交额8.72%。其中，超大单净流出191.82万 元、占成交额0.9%，大单净流出1665.43万元、占成交额7.82%，中单净流出流出858.88万元、占成交额 4.03%，小单净流入2716.14万元、占成交额12.76%。 亨迪药业最新一期业绩显示，截至2025一季报，公司营业总收入1.14亿元、同比减少17.10%，归属净利 润1032.61万元，同比减少72.38%，扣非净利润251.29万元，同比减少93.03%，流动比率13.670、速动比 率12.687、资产负债率6.10%。 天眼查商业履历信息显示，湖北亨迪药业股份有限公司，成立于1995年，位于荆门市，是一家以从事医 药制造业为主的企业。企业注册资本28800万人民币，实缴资本7020万人民币。公司法定代表人为程志 刚。 通过天眼查大数据分析，湖北亨迪药业股份有限公司共对外投资了5家企业，参与招投标项目1685次， 知 ...

Group 1 - The hepatitis concept sector experienced a short-term surge, with Kewah Bio (002022) hitting the daily limit up [1] - Other companies such as Qianyuan Pharmaceutical (300254), Hendi Pharmaceutical (301211), Da'an Gene (002030), Asia-Pacific Pharmaceutical (002370), and Kangzhi Pharmaceutical (300086) also saw significant increases in their stock prices [1]